- Home
- / Regulus Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Regulus Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.6
2024-10-29
Market Capitalization
$105.4 M
2024-10-29
Revenue
$10 M
FY, 2020
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.8M | 1.2M | 72.0K | 72.0K | 6.8M | 10.0M | ||||
| Revenue growth, % | 171.0% | -94.2% | -94.0% | |||||||
| General and administrative expense | 19.1M | 18.4M | 17.0M | 12.9M | 11.3M | 8.8M | 10.0M | 9.8M | 10.0M | 14.7M |
| Operating expense total | 75.5M | 82.7M | 70.2M | 46.8M | 23.7M | 24.2M | 28.2M | 50.0M | ||
| EBIT | (54.8M) | (81.5M) | (70.1M) | (46.8M) | (16.8M) | (14.2M) | (27.8M) | (28.2M) | (31.1M) | (50.0M) |
| EBIT margin, % | -263.8% | -6826.0% | -97404.2% | -64948.6% | -246.4% | -141.5% | ||||
| Interest income | 855.0K | 844.0K | 752.0K | 459.0K | 374.0K | 233.0K | 864.0K | 605.0K | 1.7M | 3.8M |
| Interest expense | 604.0K | 66.0K | ||||||||
| Pre tax profit | (55.8M) | (81.8M) | (72.1M) | (48.6M) | (18.6M) | (15.7M) | (27.8M) | (28.3M) | (30.0M) | (46.4M) |
| Income tax expense | (18.0K) | (4.0K) | (197.0K) | 62.0K | 1.0K | 1.0K | 1.0K | 1.0K | 1.0K | |
| Net Income | (55.7M) | (81.8M) | (71.9M) | (48.7M) | (18.6M) | (15.7M) | (27.8M) | (28.3M) | (30.0M) | (46.4M) |
| EPS | 1.9 | 1.0 | (0.8) |